Diaceutics (DXRX) Share Price, News & Analysis

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Key Stats

• Today's Range: 135 to 140
• 50-Day Range: 112.50 to 140
• 52-Week Range: 106 to 151
• Volume: 61,362 shs
• Average Volume: 148,316 shs
• Market Capitalization: £118.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 175
• Consensus Rating: Buy

DXRX Stock Analysis - Frequently Asked Questions

How have DXRX shares performed this year?

Diaceutics' stock was trading at GBX 123 at the beginning of 2025. Since then, DXRX stock has increased by 13.7% and is now trading at GBX 139.89.

How were Diaceutics' earnings last quarter?

Diaceutics PLC (LON:DXRX) issued its earnings results on Tuesday, May, 13th. The company reported ($2.02) earnings per share for the quarter. Diaceutics had a negative trailing twelve-month return on equity of 7.15% and a negative net margin of 10.90%.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Diaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/29/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:DXRX
• CIK: N/A
• Web: www.diaceutics.com
• Phone: N/A
• Fax: N/A
• Employees: 151
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Diaceutics: GBX 175
• High Price Target: GBX 185
• Low Price Target: GBX 160
• Potential Upside/Downside: +25.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (3.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 138.40
• P/E Growth: N/A
• Net Income: -£2.84 million
• Net Margins: -10.90%
• Pretax Margin: N/A
• Return on Equity: -7.15%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 4.85
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: £26.08 million
• Price / Sales: 4.53
• Cash Flow: GBX 44.84 per share
• Price / Cash Flow: 3.12
• Book Value: GBX 45.87 per share
• Price / Book: 3.05

Miscellaneous

• Outstanding Shares: 84,393,829
• Free Float: N/A
• Market Cap: £118.06 million
• Optionable: Not Optionable
• Beta: 0.58